(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Cholestasis D002779 23 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Niemann-Pick Diseases D009542 25 associated lipids
Brain Diseases D001927 27 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Acne Vulgaris D000152 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Arthritis D001168 41 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Occupational Diseases D009784 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Yang WH et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. 2013 Vaccine pmid:23856331
Lange S et al. Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors. 2013 Eur J Med Chem pmid:23583910
Rasch MR et al. Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. 2012 Langmuir pmid:23033891
Singh M et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. 2012 Hum Vaccin Immunother pmid:22832252
Vesikari T et al. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. 2012 Hum Vaccin Immunother pmid:22906943
Della Cioppa G et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. 2012 Hum Vaccin Immunother pmid:22426371
Ikematsu H et al. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. 2012 Hum Vaccin Immunother pmid:22854661
Faenzi E et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. 2012 Vaccine pmid:22521851
Hatz C et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. 2012 Vaccine pmid:22626675
Hwang SM et al. Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. 2012 Jpn. J. Infect. Dis. pmid:22627298
Siegrist CA et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. 2012 Antivir. Ther. (Lond.) pmid:22544169
Yang M et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. 2012 Int. Immunopharmacol. pmid:22595192
Cabrera-Vique C et al. Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. 2012 Nutr. Rev. pmid:22537213
Stella B et al. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. 2012 Eur J Pharm Biopharm pmid:22008147
Nakazawa A et al. Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. 2012 Bioresour. Technol. pmid:22023965
Niehaus TD et al. Functional identification of triterpene methyltransferases from Botryococcus braunii race B. 2012 J. Biol. Chem. pmid:22241476
Xue Z et al. Divergent evolution of oxidosqualene cyclases in plants. 2012 New Phytol. pmid:22150097
Oral E et al. A new mechanism of oxidation in ultrahigh molecular weight polyethylene caused by squalene absorption. 2012 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:22190411
Sancho A et al. More on influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22738111
Yang P et al. Two concise enantioselective total syntheses of (-)-glabrescol implicate alternative biosynthetic pathways starting from squalene. 2012 Org. Lett. pmid:22817611
Ramírez-Torres A et al. Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. 2012 J Proteomics pmid:22796066
Surls J et al. Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. 2012 PLoS ONE pmid:22723880
Girod A et al. Composition of fingermark residue: a qualitative and quantitative review. 2012 Forensic Sci. Int. pmid:22727572
Sarpietro MG et al. Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. 2012 Int J Pharm pmid:22728161
Wu S et al. Engineering triterpene metabolism in tobacco. 2012 Planta pmid:22729821
Langley JM et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. 2012 Pediatr. Infect. Dis. J. pmid:22801094
Block SL et al. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. 2012 Pediatr. Infect. Dis. J. pmid:22481427
Sémiramoth N et al. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. 2012 ACS Nano pmid:22482704
Langley JM et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. 2012 Vaccine pmid:22469860
Fukase H et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. 2012 Vaccine pmid:22472791
Suthiwong J et al. A new phenolic compound from the stem of Hymenocardia wallichii. 2012 J Asian Nat Prod Res pmid:22423644
Zhang XH et al. Chemical composition of volatile oils from the pericarps of Indian sandalwood (Santalum album) by different extraction methods. 2012 Nat Prod Commun pmid:22428257
Guzmán Herrador BR et al. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. 2012 BMC Infect. Dis. pmid:22429643
Hatz C et al. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. 2012 Vaccine pmid:22446638
Dell'Era L et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. 2012 Vaccine pmid:22138210
Allain V et al. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. 2012 Nucleic Acids Res. pmid:22075995
Dey AK et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 2012 Vaccine pmid:22366638
Garçon N et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. 2012 Expert Rev Vaccines pmid:22380826
Ramírez-Torres A et al. Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. 2012 J Proteomics pmid:22402057
Tronchoni J et al. Lipid composition of wine strains of Saccharomyces kudriavzevii and Saccharomyces cerevisiae grown at low temperature. 2012 Int. J. Food Microbiol. pmid:22405355
Fox CB et al. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. 2012 AAPS PharmSciTech pmid:22415641
Nassim C et al. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. 2012 Pediatr. Infect. Dis. J. pmid:22418661
Fox CB et al. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. 2012 Clin. Vaccine Immunol. pmid:22896687
Reynales H et al. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. 2012 Vaccine pmid:22902681
Desmaële D et al. Squalenoylation: a generic platform for nanoparticular drug delivery. 2012 J Control Release pmid:21840355
Naziri E et al. Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. 2012 J. Agric. Food Chem. pmid:22888984
Liu Y et al. [Researches on influence of squalene synthase gene polymorphism on catalytic efficiency of its encode enzyme in Glycyrrhiza uralensis]. 2012 Zhongguo Zhong Yao Za Zhi pmid:23627178
Czajka H et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. 2012 J Prev Med Hyg pmid:23362618
Takami T et al. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. 2012 PLoS ONE pmid:23145048
Langley JM et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. 2012 BMC Infect. Dis. pmid:23110320